Matinas BioPharma Holdings, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Details
| Name | Matinas BioPharma Holdings, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 2 |
| Founded | 2013 |
| Ceo | Jerome Jabbour |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US5768104029 |
| Cusip | 576810402 |
| Cik | 0001582554 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Jerome D. Jabbour J.D. | Co-Founder, Chairman, Chief Executive Officer, President and Interim Chief Financial Officer |
Contact
| Address | 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921, United States |
| Phone | 908 484 8805 |
| Website | https://www.matinasbiopharma.com |